Neuralstem ALS Trial in Multiple Presentations at Upcoming American Academy of Neurology Meeting

<!--endclickprintexclude-->ROCKVILLE,
Md., April 6, 2011
/PRNewswire/ -- Neuralstem, Inc. announced that the Phase I safety trial of
its human spinal cord stem cells (HSSCs) in amyotrophic lateral
sclerosis (ALS or Lou Gehrig's
disease) is the subject of three presentations at the American
Academy of Neurology (AAN) Annual Meeting, April 9-16th, in Honolulu, HI (http://www.aan.com/go/am11). Chief among these will be
a presentation by Eva Feldman, M.D.,
Ph.D., who is an unpaid consultant to Neuralstem and the Principal
Investigator in the ongoing ALS trial, entitled: "A Phase I,
Open-Label, First-In-Human Feasibility and Safety Study of Human
Spinal Cord-Derived Neural Stem Cell Transplantation for the
Treatment of Amyotrophic Lateral Sclerosis," at 2:00 PM, April
11th, (http://www.abstracts2view.com/aan/view.php?nu=AAN11L_P01.287).
Dr. Feldman, who is also Director of the A. Alfred Taubman Medical
Research Institute and Director of Research of the ALS Clinic at
the University of Michigan Health
System, will present interim safety data on the first nine patients
in the study.

Dr. Feldman's presentation was also chosen to be highlighted in
the "Scientific Program Highlights Plenary Session" mediated by the
Chair of the AAN Science Committee at 5:15 on April 15th. Inclusion in this session is by
invitation only; Dr. Feldman's presentation was considered by the
committee to be in the top 5% of submitted abstracts, which
numbered in the thousands.

"We are thrilled to receive this level of interest and review
from our peers at this prestigious neurology conference," Dr.
Feldman commented. "As a doctor who sees ALS patients in the
clinic, I am particularly eager to share this promising research
with the scientists and clinicians of the American Academy of
Neurology who continue to battle this difficult disease for their
patients."

In addition to Dr. Feldman's presentation, two others will focus
on the Neuralstem ALS stem cell trial. Dr. Jonathan Glass, M.D., professor of neurology,
Emory School of Medicine and Director of the Emory ALS Center, will
join Dr. Nicholas Boulis, M. D.,
associate professor of neurosurgery at Emory School of Medicine,
and Dr. Feldman for a presentation entitled: "Intraoperative Evoked
Potentials for Monitoring Spinal Cord Stem Cell Injection in
Patients with ALS," at 2:00 on April
14th. Dr. Glass is the site Principal Investigator for the
trial and Dr. Boulis is performing the surgeries. The team will be
joined by neurologist Seward Rutkove, MD, Chief of
the Division of Neuromuscular Disease at Beth
Israel Deaconess Medical Center, to present "Electrical Impedance
Myography in a Safety Study of Fetal Stem Cell Implantation in
Amyotrophic Lateral Sclerosis," at 5:00 on April 14th. Dr. Rutkove's innovative work
in EIM, which uses electrical currents to measure muscle changes in
ALS patients, was just awarded a $1
million Prize4Life award (http://www.prize4life.org/). Neuralstem's trial
is the first ALS study to utilize this breakthrough technology.

About the Trial

This Phase I trial, which is evaluating the safety of the cells
and the surgery procedure, is designed to enroll up to 18 ALS
patients, at varying stages of the disease progression. 11 patients
have been treated so far. The first six were non-ambulatory. Of
these, the first three received five unilateral injections of HSSCs
in the L2-L4 lumbar segments of the spinal cord. The next three
received 10 bilateral injections. All of the subsequent patients
were ambulatory. The first three of these received five unilateral
injections in the L2-L4 lumbar segments. The next two have received
10 unilateral injections in the same region. Future patients
will all be ambulatory with sequential levels of disability. If
approved by the FDA and the trial's safety monitoring board (SMB),
the trial will progress to cervical transplantation.

About Neuralstem

Neuralstem's patented technology enables the ability to produce
neural stem cells of the human brain and spinal cord in commercial
quantities, and the ability to control the differentiation of these
cells constitutively into mature, physiologically relevant human
neurons and glia. Neuralstem is in a FDA-approved Phase I safety
clinical trial for amyotrophic lateral sclerosis (ALS), often
referred to as Lou Gehrig's disease
and has been awarded orphan status designation by the FDA.

In addition to ALS, the company is also targeting major central
nervous system diseases, including traumatic spinal cord injury,
ischemic spastic paraplegia, and Huntington's disease. The company has also
submitted an IND (Investigational New Drug) application to the FDA
for a Phase I safety trial in chronic spinal cord injury.

Neuralstem also has the ability to generate stable human neural
stem cell lines suitable for the systematic screening of large
chemical libraries. Through this proprietary screening technology,
Neuralstem has discovered and patented compounds that may stimulate
the brain's capacity to generate new neurons, possibly reversing
the pathologies of some central nervous system conditions.
The company has commenced a FDA-approved Phase Ia safety
trial evaluating NSI-189, its first small molecule compound, for
the treatment of major depression. Additional indications
could include schizophrenia, Alzheimer's disease, traumatic brain
injury, posttraumatic stress syndrome, and stroke.

Cautionary Statement Regarding Forward Looking
Information

This news release may contain forward-looking statements made
pursuant to the "safe harbor" provisions of the Private Securities
Litigation Reform Act of 1995. Investors are cautioned that such
forward-looking statements in this press release regarding
potential applications of Neuralstem's technologies constitute
forward-looking statements that involve risks and uncertainties,
including, without limitation, risks inherent in the development
and commercialization of potential products, uncertainty of
clinical trial results or regulatory approvals or clearances, need
for future capital, dependence upon collaborators and maintenance
of our intellectual property rights. Actual results may differ
materially from the results anticipated in these forward-looking
statements. Additional information on potential factors that could
affect our results and other risks and uncertainties are detailed
from time to time in Neuralstem's periodic reports, including the
annual report on Form 10-K for the year ended December 31, 2010.